ZA200807678B - Meridamycin analogues for the treatment of neurodegenerative disorders - Google Patents

Meridamycin analogues for the treatment of neurodegenerative disorders

Info

Publication number
ZA200807678B
ZA200807678B ZA200807678A ZA200807678A ZA200807678B ZA 200807678 B ZA200807678 B ZA 200807678B ZA 200807678 A ZA200807678 A ZA 200807678A ZA 200807678 A ZA200807678 A ZA 200807678A ZA 200807678 B ZA200807678 B ZA 200807678B
Authority
ZA
South Africa
Prior art keywords
treatment
neurodegenerative disorders
meridamycin
analogues
meridamycin analogues
Prior art date
Application number
ZA200807678A
Other languages
English (en)
Inventor
Graziani Edmund Idris
Pong Kevin
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ZA200807678B publication Critical patent/ZA200807678B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
ZA200807678A 2006-03-07 2008-09-05 Meridamycin analogues for the treatment of neurodegenerative disorders ZA200807678B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77994006P 2006-03-07 2006-03-07

Publications (1)

Publication Number Publication Date
ZA200807678B true ZA200807678B (en) 2009-08-26

Family

ID=38289934

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200807678A ZA200807678B (en) 2006-03-07 2008-09-05 Meridamycin analogues for the treatment of neurodegenerative disorders

Country Status (19)

Country Link
US (1) US7745457B2 (enExample)
EP (1) EP1991551A1 (enExample)
JP (1) JP2009529049A (enExample)
KR (1) KR20080099317A (enExample)
CN (1) CN101426796A (enExample)
AR (1) AR059738A1 (enExample)
AU (1) AU2007223962A1 (enExample)
BR (1) BRPI0708611A2 (enExample)
CA (1) CA2643350A1 (enExample)
CR (1) CR10272A (enExample)
EC (1) ECSP088718A (enExample)
IL (1) IL193414A0 (enExample)
MX (1) MX2008011312A (enExample)
NO (1) NO20083695L (enExample)
PE (1) PE20081550A1 (enExample)
RU (1) RU2008132779A (enExample)
TW (1) TW200804400A (enExample)
WO (1) WO2007103347A1 (enExample)
ZA (1) ZA200807678B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1828203A2 (en) * 2004-12-20 2007-09-05 Wyeth Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
RU2394036C2 (ru) * 2004-12-20 2010-07-10 Вайет Аналоги рапамицина и их применение при лечении неврологических, пролиферативных и воспалительных заболеваний

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9302016D0 (en) 1993-02-02 1993-03-17 Sandoz Ltd Compounds
GB9318144D0 (en) 1993-09-01 1993-10-20 Sandoz Ltd Organic compounds
EP0729471A1 (en) 1993-11-19 1996-09-04 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US20050197356A1 (en) * 2004-03-02 2005-09-08 Wyeth Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents
BRPI0508224A (pt) 2004-03-02 2007-07-17 Wyeth Corp composto ou um sal farmaceuticamente aceitável do mesmo, cepa de actinomiceto, isolado de uma cepa, métodos para a produção de um macrolìdeo e de um composto, produto, composição, métodos de tratamento de um mamìfero e de um distúrbio neurológico, e, uso de um composto
JP2008501342A (ja) 2004-06-03 2008-01-24 ワイス 複合ポリケチドを生成するための生合成遺伝子クラスター
US7595187B2 (en) * 2004-11-12 2009-09-29 Wyeth Elaiophylin biosynthetic gene cluster
EP1828203A2 (en) 2004-12-20 2007-09-05 Wyeth Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
RU2394036C2 (ru) 2004-12-20 2010-07-10 Вайет Аналоги рапамицина и их применение при лечении неврологических, пролиферативных и воспалительных заболеваний

Also Published As

Publication number Publication date
US7745457B2 (en) 2010-06-29
AU2007223962A1 (en) 2007-09-13
KR20080099317A (ko) 2008-11-12
RU2008132779A (ru) 2010-04-20
EP1991551A1 (en) 2008-11-19
CA2643350A1 (en) 2007-09-13
CR10272A (es) 2008-10-03
MX2008011312A (es) 2008-09-12
US20070213525A1 (en) 2007-09-13
WO2007103347A1 (en) 2007-09-13
ECSP088718A (es) 2008-10-31
BRPI0708611A2 (pt) 2011-06-07
TW200804400A (en) 2008-01-16
NO20083695L (no) 2008-10-03
CN101426796A (zh) 2009-05-06
PE20081550A1 (es) 2008-12-31
IL193414A0 (en) 2009-05-04
AR059738A1 (es) 2008-04-23
JP2009529049A (ja) 2009-08-13

Similar Documents

Publication Publication Date Title
IL187168A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
IL192692A0 (en) Compounds for the treatment of inflammatory disorders
EP1976377A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
EP1983972A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
IL195203A0 (en) Compounds for the treatment of metabolic disorders
ZA200805645B (en) Compounds for the treatment of metabolic disorders
ZA200806455B (en) Use of 2-imidazoles for the treatment of CNS disorders
IL198856A0 (en) Compounds useful for treating neurodegenerative disorders
IL193799A0 (en) New therapeutic combinations for the treatment or prevention of psycotic disorders
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
IL192877A0 (en) Use of 2-imidazoles for the treatment of cns disorders
ZA200805108B (en) Treatment of neurodegenerative disorders
ZA200802270B (en) Treatment of neurodegenerative disorders
IL195392A0 (en) Compounds for the treatment of metabolic disorders
IL192851A0 (en) Compounds for the treatment of metabolic disorders
IL196643A0 (en) Methods and tools for the therapy of neurodegenerative pathologies
IL198432A0 (en) 2-alkyl-indazole compounds for the treatment of certain cns-related disorders
IL193414A0 (en) Meridamycin analogues for the treatment ofneurodegenererative disorders
IL192982A0 (en) Compounds for the treatment of metabolic disorders
GB0602857D0 (en) The treatment of sialorrhoea
HK1120220A (en) Treatment of neurodegenerative disorders
PT1842537E (pt) Utilização de um composto anti-aterotrombótico para a obtenção de medicamentos destinados ao tratamento de perturbações cerebro-vasculares
GB0724947D0 (en) Composition for the treatment of psychiatric disorders
GB0715255D0 (en) Thiadiazol-piperazinyl derivatives for the treatment of neurodegenerative diseases
GB0602855D0 (en) The Treatment Of Sialorrhoea